MimiVax Cancer Vaccine Failed Phase 2 Clinical Trial
The experimental treatment SurVaxM missed its primary efficacy endpoint in a study of glioblastoma patients.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Should companies continue developing drugs if clinical trials fail to meet their primary efficacy endpoints?
MimiVax announced that its cancer vaccine, SurVaxM, did not meet the primary endpoint in a phase 2 clinical trial involving 233 patients. While the treatment failed the study's overall goals, the company reported potential survival benefits in a specific subgroup of patients aged 65 and younger.
Why it matters
The trial failure is significant given that no new glioblastoma drug has received regulatory approval in over 20 years. The vaccine is designed to target survivin, a protein that prevents programmed cell death in tumor cells.
In the study of 233 evaluable patients, 44% of SurVaxM recipients aged 65 and younger reached 12-month progression-free survival compared to 24% of placebo recipients. Grade 3 or higher adverse events affected 48% of the treatment group and 46% of the placebo group.
The players
MimiVax
A biotechnology company headquartered in New York that focuses on developing immunotherapies for cancer.
Roswell Park Comprehensive Cancer Center
A research and treatment facility located in Buffalo, New York, where the SurVaxM vaccine originated.
BrainChild Bio
A biotech firm preparing to enter clinical trials for a pediatric brain cancer therapy next year.
The details
Patients in the trial received four primary injections over two weeks, followed by booster injections every two months alongside standard-of-care therapy consisting of surgery, chemotherapy, and radiation. MimiVax plans to continue pursuing a path toward potential FDA approval for the vaccine despite missing the primary study endpoint.
Timeline
2005: Temozolomide was added as a standard-of-care treatment for glioblastoma.
2012: MimiVax was spun out of the Roswell Park Comprehensive Cancer Center.
2022: The phase 2a clinical trial of the SurVaxM vaccine concluded.
October 7, 2026: MimiVax officially announced the results of the phase 2 study.
Next year: BrainChild Bio expects to enter the clinic with a pediatric brain cancer therapy.
The Big Picture
The failure of the SurVaxM trial marks the continuation of a two-decade-long drought in new drug approvals for glioblastoma that has persisted since the 2005 establishment of temozolomide as standard-of-care. This result highlights the ongoing difficulty in surpassing the efficacy standards set by established historical protocols.
Patients currently managing glioblastoma should consult their healthcare providers, as this trial result means SurVaxM is not yet an available clinical treatment option. The findings may eventually influence future clinical trial designs or potential treatment pathways for specific age demographics.
The takeaway
While SurVaxM failed its primary trial goal, the survival data observed in younger patients offers a potential area for future study. Researchers often rely on these subgroup findings to refine protocols and identify specific patient populations that may better respond to immunotherapy.
Further reading
For more information on ongoing research and developments, visit the Cancer section.
Live Poll
Should companies continue developing drugs if clinical trials fail to meet their primary efficacy endpoints?
